



## 2025 Recommended Pediatric and Adolescent Immunization Schedule (Maintains CPP Eligibility)

Manufacturer	Brand Name	Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16-18 yrs			
Sanofi	Beyfortus®	RSV-mAb	1st Dose depending on maternal RSV vaccination					1 dose thru 19 months													
Merck MSP	Recombivax HB® Vaxelis®	Hepatitis B	1st	2nd		3rd															
Merck	RotaTeq®	Rotavirus (oral)		1st	2nd	3rd															
Sanofi Sanofi MSP Sanofi	Daptacel® Pentacel® Vaxelis® Quadracel®	Diphtheria, Tetanus, Acellular Pertussis (DTaP)		1st		2nd		3rd		4th		5th									
Sanofi Merck Sanofi MSP	ActHIB® PedVaxHIB® Pentacel® Vaxelis®	Haemophilus Influenzae Type B		1st		2nd		3rd		4th											
Pfizer Merck	Prevnar 20® Vaxneuvance®	Pneumococcal Conjugate		1st		2nd		3rd		4th											
Sanofi Sanofi MSP Sanofi	IPOL® Pentacel® Vaxelis® Quadracel®	Inactivated Polio		1st		2nd		3rd		4th											
Various	Various	COVID-19						1 or more doses of updated vaccine													
Sanofi	Fluzone®	Influenza (IIV)						Annual Vaccination 1 or 2 doses							Annual Vaccination 1 dose only						
<b>OR</b>			<b>OR</b>																		
AstraZeneca	FluMist®	Influenza (LAIV4)													Annual Vaccination 1 or 2 doses		Annual Vaccination 1 dose only				
Merck	MMRII® ProQuad®	Measles, Mumps, Rubella								1st				2nd							
Merck	Varivax® ProQuad®	Varicella								1st				2nd							
Merck	Vaqta®	Hepatitis A								2 dose series											
Sanofi	Adacel®	Tetanus, Diphtheria, Acellular Pertussis (Tdap)													Tdap						
Merck	Gardasil 9®	Human Papillomavirus													2 dose series						
Sanofi Pfizer	MenQuadfi® Penbraya™	MenACWY MenABCWY																1st		2nd	
Pfizer	Trumenba® Penbraya™	MenB MenABCWY																			
Pfizer	Abrysvo®	RSV maternal																Seasonal administration during pregnancy			
Sanofi	Dengvaxia®	Dengue																seropositive in endemic dengue areas			
	JYNNEOS vaccine	Monkeypox																			

Range of recommended ages

Catch-up vaccination

High risk population

Non-high-risk groups may receive vaccine,  
subject to shared clinical decision making

The information in this document is proprietary and confidential and may not be disclosed without the written consent of Children's Practicing Pediatricians. This information may be used solely by medical practices and practitioners for the purpose of evaluating the CPP Vaccine Buying Group. The information can become outdated quickly and should be used only as an illustration of some of the benefits of the CPP Program. No clinical, medical or professional advice is being rendered and readers should discuss specific situations within each practice and/or with their professional advisors. Copyright 2024 by Children's Practicing Pediatricians. All rights reserved.